Novartis AG ADR (NVS)vsVSee Health, Inc. (VSEE)
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $282.11B
VSEE
VSee Health, Inc.
$0.19
+2.22%
HEALTHCARE · Cap: $9.01M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 386938% more annual revenue ($56.58B vs $14.62M). NVS leads profitability with a 23.9% profit margin vs -100.6%. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
VSEE
Avoid32
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$147.85
$38.25 premium
Intrinsic value data unavailable for VSEE.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Conservative balance sheet, low leverage
Areas to Watch
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -542.0% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : VSEE
The strongest argument for VSEE centers on Debt/Equity.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Bear Case : VSEE
The primary concerns for VSEE are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
NVS profiles as a declining stock while VSEE is a turnaround play — different risk/reward profiles.
VSEE carries more volatility with a beta of 0.65 — expect wider price swings.
VSEE is growing revenue faster at 5.1% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 32/100), backed by strong 23.9% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →VSee Health, Inc.
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
VSee Health, Inc. is a leading innovator in the telehealth sector, offering secure, user-friendly video communication solutions tailored for healthcare providers and patients. Its comprehensive platform encompasses a range of functionalities such as remote patient monitoring, asynchronous messaging, and seamless electronic medical record (EMR) interoperability, all designed to enhance the efficiency and quality of healthcare delivery across various specialties. With a strong commitment to improving patient engagement and accessibility, VSee caters to a diverse global clientele, positioning itself to capitalize on the growing demand for virtual care in the evolving healthcare landscape. As the industry shifts towards digital solutions, VSee Health is poised for significant growth through its cutting-edge technology and strategic initiatives.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?